Abstract
Sixty-one patients with ST elevation acute myocardial infarction were randomized to receive open-label tirofiban in the emergency room before primary angioplasty versus glycoprotein IIb/IIIa inhibitors administered after initial coronary angiography. Early administration of tirofiban before primary angioplasty resulted in nonsignificant improvement in initial coronary flow (Thrombolysis In Myocardial Infarction trial grade 2 or 3 flow, 39% vs 27%, p >0.20). Patients receiving early tirofiban treatment were more likely to achieve complete (>70%) ST-segment resolution at 90 minutes (69% vs 44%, p = 0.07).
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Angioplasty, Balloon, Coronary*
-
Coronary Angiography
-
Electrocardiography
-
Emergency Treatment
-
Female
-
Humans
-
Male
-
Middle Aged
-
Myocardial Infarction / therapy*
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
-
Postoperative Care*
-
Preoperative Care*
-
Tirofiban
-
Treatment Outcome
-
Tyrosine / analogs & derivatives*
-
Tyrosine / therapeutic use*
Substances
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Tyrosine
-
Tirofiban